Publicaciones en colaboración con investigadores/as de University of Toronto (58)

2023

  1. Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis

    CMAJ. Canadian Medical Association Journal, Vol. 66, Núm. 3, pp. E310-E320

  2. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

    British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294

2022

  1. Mood Disturbances Across the Continuum of Care Based on Self-Report and Clinician Rated Measures in the interRAI Suite of Assessment Instruments

    Frontiers in Psychiatry, Vol. 13

  2. Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis

    Therapeutic Advances in Medical Oncology, Vol. 14

2021

  1. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

    The Lancet Oncology, Vol. 22, Núm. 5, pp. 727-736

  2. Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19

    New England Journal of Medicine, Vol. 385, Núm. 9, pp. 790-802

2020

  1. A reference map of the human binary protein interactome

    Nature, Vol. 580, Núm. 7803, pp. 402-408

  2. HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates

    Breast Cancer Research, Vol. 22, Núm. 1

  3. Integrin ανβ6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis

    Molecular Diagnosis and Therapy, Vol. 24, Núm. 2, pp. 143-151

2019

  1. Comparative genomics of the major parasitic worms

    Nature Genetics, Vol. 51, Núm. 1, pp. 163-174

  2. Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome

    OncoImmunology, Vol. 8, Núm. 10

  3. Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors

    PLoS ONE, Vol. 14, Núm. 4

  4. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

    European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973

  5. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial

    The Lancet, Vol. 394, Núm. 10206, pp. 1325-1334

  6. Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis

    Frontiers in Oncology, Vol. 9

2018

  1. Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: Understanding clinical trial results

    Oncotarget, Vol. 9, Núm. 61, pp. 31915-31919

  2. Encompassing new use cases - Level 3.0 of the HUPO-PSI format for molecular interactions

    BMC Bioinformatics, Vol. 19, Núm. 1

  3. Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer

    Breast Cancer Research and Treatment, Vol. 172, Núm. 3, pp. 725-732

  4. Functional transcriptomic annotation and protein–protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer

    Cancer Medicine, Vol. 7, Núm. 5, pp. 1896-1907

2017

  1. Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis

    American Heart Journal, Vol. 193, pp. 46-54